Literature DB >> 31776266

An Alu Element Insertion in Intron 1 Results in Aberrant Alternative Splicing of APOBEC3G Pre-mRNA in Northern Pig-Tailed Macaques (Macaca leonina) That May Reduce APOBEC3G-Mediated Hypermutation Pressure on HIV-1.

Xiao-Liang Zhang1,2, Meng-Ting Luo1,3, Jia-Hao Song1,4, Wei Pang1, Yong-Tang Zheng5,3.   

Abstract

APOBEC3 family members, particularly APOBEC3F and APOBEC3G, inhibit the replication and spread of various retroviruses by inducing hypermutation in newly synthesized viral DNA. Viral hypermutation by APOBEC3 is associated with viral evolution, viral transmission, and disease progression. In recent years, increasing attention has been paid to targeting APOBEC3G for AIDS therapy. Thus, a controllable model system using species such as macaques, which provide a relatively ideal in vivo system, is needed for the study of APOBEC3-related issues. To appropriately utilize this animal model for biomedical research, important differences between human and macaque APOBEC3s must be considered. In this study, we found that the ratio of APOBEC3G-mediated/APOBEC3-mediated HIV-1 hypermutation footprints was much lower in peripheral blood mononuclear cells (PBMCs) from northern pig-tailed macaques than in PBMCs from humans. Next, we identified a novel and conserved APOBEC3G pre-mRNA alternative splicing pattern in macaques, which differed from that in humans and resulted from an Alu element insertion into macaque APOBEC3G gene intron 1. This alternative splicing pattern generating an aberrant APOBEC3G mRNA isoform may significantly dilute full-length APOBEC3G and reduce APOBEC3G-mediated hypermutation pressure on HIV-1 in northern pig-tailed macaques, which was supported by the elimination of other possibilities accounting for this hypermutation difference between the two hosts.IMPORTANCE APOBEC3 family members, particularly APOBEC3F and APOBEC3G, are important cellular antiviral factors. Recently, more attention has been paid to targeting APOBEC3G for AIDS therapy. To appropriately utilize macaque animal models for the study of APOBEC3-related issues, it is important that the differences between human and macaque APOBEC3s are clarified. In this study, we identified a novel and conserved APOBEC3G pre-mRNA alternative splicing pattern in macaques, which differed from that in humans and which may reduce the APOBEC3G-mediated hypermutation pressure on HIV-1 in northern pig-tailed macaques (NPMs). Our work provides important information for the proper application of macaque animal models for APOBEC3-related issues in AIDS research and a better understanding of the biological functions of APOBEC3 proteins.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  APOBEC3G; HIV-1; Macaca leoninazzm321990; alternative splicing; northern pig-tailed macaques

Mesh:

Substances:

Year:  2020        PMID: 31776266      PMCID: PMC6997765          DOI: 10.1128/JVI.01722-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Genomewide comparative analysis of alternative splicing in plants.

Authors:  Bing-Bing Wang; Volker Brendel
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.

Authors:  Terumasa Ikeda; Amy M Molan; Matthew C Jarvis; Michael A Carpenter; Daniel J Salamango; William L Brown; Reuben S Harris
Journal:  J Gen Virol       Date:  2019-05-30       Impact factor: 3.891

3.  Molecular cloning and anti-HIV-1 activities of APOBEC3s from northern pig-tailed macaques (Macaca leonina).

Authors:  Xiao-Liang Zhang; Jia-Hao Song; Wei Pang; Yong-Tang Zheng
Journal:  Dongwuxue Yanjiu       Date:  2016-07-18

4.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

5.  Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.

Authors:  Evguenia S Svarovskaia; Hongzhan Xu; Jean L Mbisa; Rebekah Barr; Robert J Gorelick; Akira Ono; Eric O Freed; Wei-Shau Hu; Vinay K Pathak
Journal:  J Biol Chem       Date:  2004-06-20       Impact factor: 5.157

6.  APOBEC3H polymorphisms and susceptibility to HIV-1 infection in an Indian population.

Authors:  Taeko K Naruse; Daisuke Sakurai; Hitoshi Ohtani; Gaurav Sharma; Surendra K Sharma; Madhu Vajpayee; Narinder K Mehra; Gurvinder Kaur; Akinori Kimura
Journal:  J Hum Genet       Date:  2015-11-12       Impact factor: 3.172

7.  Stably expressed APOBEC3H forms a barrier for cross-species transmission of simian immunodeficiency virus of chimpanzee to humans.

Authors:  Zeli Zhang; Qinyong Gu; Marc de Manuel Montero; Ignacio G Bravo; Tomas Marques-Bonet; Dieter Häussinger; Carsten Münk
Journal:  PLoS Pathog       Date:  2017-12-21       Impact factor: 6.823

8.  HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G.

Authors:  Terumasa Ikeda; Menelaos Symeonides; John S Albin; Ming Li; Markus Thali; Reuben S Harris
Journal:  PLoS Pathog       Date:  2018-04-20       Impact factor: 6.823

9.  Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance.

Authors:  Patric Jern; Rebecca A Russell; Vinay K Pathak; John M Coffin
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

10.  Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease.

Authors:  Diako Ebrahimi; Christopher M Richards; Michael A Carpenter; Jiayi Wang; Terumasa Ikeda; Jordan T Becker; Adam Z Cheng; Jennifer L McCann; Nadine M Shaban; Daniel J Salamango; Gabriel J Starrett; Jairam R Lingappa; Jeongsik Yong; William L Brown; Reuben S Harris
Journal:  Nat Commun       Date:  2018-10-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.